Drugs / P1446A-05
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02117336 | Jun 2014 → Oct 2016 | B-cell chronic lymphocytic leukemia | Piramal Enterprises Limited | Suspended | No outcome recorded |
| Phase 1 | NCT01841463 | Aug 2013 → Mar 2015 | melanoma | Piramal Enterprises Limited | Suspended | No outcome recorded |
| Phase 1 | NCT00772876 | Dec 2008 → Apr 2012 | cancer | Piramal Enterprises Limited | Completed | No outcome recorded |
| Phase 1 | NCT00840190 | Dec 2008 → Mar 2011 | cancer, hematopoietic and lymphoid cell neoplasm | Piramal Enterprises Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P1446A-05 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01841463 ↗ |
| Action | Inhibit | “Selective Cyclin Dependent Kinase Inhibitor P1446A-05” NCT00772876 ↗ |
| Route | Oral | “75 mg orally once daily” NCT00840190 ↗ |